Seeking Alpha

Amarin (AMRN +2.3%) gains after Aegis Capital initiated the shares with a Buy this morning and a...

Amarin (AMRN +2.3%) gains after Aegis Capital initiated the shares with a Buy this morning and a 12-month price target of $25. Aegis cites the "compelling efficacy" of the company's lead drug candidate, a heart drug derived from fish oil. Aegis notes the drug's ability to not only lower high levels of triglycerides but also LDL levels gives it an advantage over current omega-3 fatty acid- derived drugs currently on the market.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|